Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, particularly cannabidiol (CBD), are increasingly studied for their role in supporting or treating anxiety disorders. Scientific interest has grown due to preclinical studies and emerging human clinical trials. The endocannabinoid system, which phytocannabinoids modulate, is implicated in anxiety regulation. Several animal studies demonstrate anxiolytic effects of CBD, showing reductions in anxiety-like behaviors. Human research is more limited but promising. For example, a 2011 double-blind study found that CBD significantly reduced social anxiety in participants subjected to a simulated public speaking test. Another small trial reported decreased anxiety in individuals with generalized social anxiety disorder after CBD administration.

However, the quality and quantity of evidence remain moderate. Most clinical studies have small sample sizes, short durations, and sometimes lack rigorous controls. There are also inconsistencies, as certain studies using tetrahydrocannabinol (THC), another prominent phytocannabinoid, report increased anxiety, especially at higher doses. Major health organizations currently regard the evidence as preliminary. While anecdotal reports and some clinical data suggest CBD may help with anxiety, more large-scale, long-term randomized controlled trials are required to confirm efficacy, optimal dosing, and safety.

In summary, there is scientific rationale and some clinical validation for the use of phytocannabinoids, particularly CBD, in managing anxiety disorders, but the evidence is not yet robust or conclusive. The current rating reflects moderate support pending further research.

More about phytocannabinoids
More about Anxiety Disorders

Other ingredients used for Anxiety Disorders

Other health conditions supported by phytocannabinoids

Products containing phytocannabinoids